DIVIS LABORATORIES
Back to Balance Sheet
|
DIVIS LABORATORIES Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹2,248 Cr | ₹1,755 Cr | ₹1,539 Cr | ₹2,454 Cr | ₹1,728 Cr |
What is the latest Total Current Liabilities ratio of DIVIS LABORATORIES ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹2,248 Cr |
| Mar2024 | ₹1,755 Cr |
| Mar2023 | ₹1,539 Cr |
| Mar2022 | ₹2,454 Cr |
| Mar2021 | ₹1,728 Cr |
How is Total Current Liabilities of DIVIS LABORATORIES Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹2,248 Cr | 28.09 | |
| Mar2024 | ₹1,755 Cr | 14.04 | |
| Mar2023 | ₹1,539 Cr | -37.30 | |
| Mar2022 | ₹2,454 Cr | 42.01 | |
| Mar2021 | ₹1,728 Cr | - | |
Compare Total Current Liabilities of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹165,511.4 Cr | -5.8% | -1.6% | 10.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹400,497.0 Cr | -3.5% | -6.4% | -2.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹136,013.0 Cr | 1.4% | 7% | 23.7% | Stock Analytics | |
| CIPLA | ₹112,922.0 Cr | -4.7% | -6.8% | -0.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,115.0 Cr | -2.8% | -8.1% | -11.1% | Stock Analytics | |
| MANKIND PHARMA | ₹89,832.6 Cr | -1.1% | 3.3% | -13.4% | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | -5.8% |
-1.6% |
10.9% |
| SENSEX | -0.7% |
-1.9% |
8% |
You may also like the below Video Courses